Modelling genetic and clinical heterogeneity in epithelial ovarian cancers

被引:30
作者
Lawrenson, Kate
Sproul, Duncan [2 ]
Grun, Barbara [1 ]
Notaridou, Maria [1 ]
Benjamin, Elizabeth [3 ]
Jacobs, Ian J. [1 ]
Dafou, Dimitra [1 ]
Sims, Andrew H. [2 ]
Gayther, Simon A. [1 ]
机构
[1] UCL, Gynaecol Canc Res Labs, UCL EGA Inst Womens Hlth, London WC1E 6DD, England
[2] Western Gen Hosp, Appl Bioinformat Canc Grp, Edinburgh Breakthrough Res Ctr, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
[3] UCL, Dept Histopathol, Inst Canc, London WC1E 6JJ, England
基金
英国医学研究理事会;
关键词
EXPRESSION PROFILES; BORDERLINE TUMORS; GROWTH-FACTOR; LOW-GRADE; C-MYC; MUTATIONS; CARCINOMA; CELLS; KRAS; TRANSFORMATION;
D O I
10.1093/carcin/bgr140
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The biology underlying early-stage epithelial ovarian cancer (EOC) development is poorly understood. Identifying biomarkers associated with early-stage disease could have a significant impact on reducing mortality. Here, we describe establishment of a three-dimensional (3D) in vitro genetic model of EOC initiation and early-stage neoplastic progression. Normal primary ovarian epithelial (POE) cells, immortalized using hTERT (immortalised ovarian epithelial [IOE] cells), were partially transformed by overexpressing the CMYC oncogene (IOECMYC cells). Subsequent expression of mutant alleles of KRAS (KRAS(G12V)) or BRAF (BRAF(V600E)) created double-mutant lines (IOECMYC.KRAS and IOECMYC.BRAF). The transformed phenotype of IOECMYC cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOECMYC cells had undergone morphological and phenotypic changes characteristic of neoplastic progression. When cultured as 3D spheroids, IOE cells underwent growth arrest, reminiscent of nonproliferative, unstimulated POE in vivo. In contrast, IOSECMYC+BRAF/KRAS cells formed highly proliferative, poly-aggregate spheroid structures, showing increased expression of the Wilms tumour 1 tumourigenic marker and MIB1 proliferation marker. Transcriptomic analyses identified different gene expression profiles between the different cell lines and novel candidate genes (e.g. RGS4, CTGF and THBS1) that are somatically altered in EOCs. Gene expression signatures were compared with signatures from primary EOCs; tumours with IOECMYC 'like' signatures were more likely to be high grade (P = 0.018); tumours with BRAF signatures were associated with improved relapse-free survival (P = 0.003). In conclusion, we have established in vitro 3D models of early-stage EOCs, which reflect genetic and phenotypic heterogeneity of the disease. Molecular genetic characteristics of these models correlated with molecular and clinical features of primary EOCs.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 50 条
  • [31] Chemoresistance Is Associated with MUC1 and Lewis y Antigen Expression in Ovarian Epithelial Cancers
    Zhang, Danye
    Gao, Jian
    Zhu, Liancheng
    Hu, Zhenhua
    Hou, Rui
    Liu, Shuice
    Tan, Mingzi
    Liu, Juanjuan
    Lin, Bei
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (06): : 11024 - 11033
  • [32] Etiology and pathogenesis of epithelial ovarian cancer
    Mok, Samuel C.
    Kwong, Joseph
    Welch, William R.
    Samimi, Goli
    Ozbun, Laurent
    Bonome, Tomas
    Birrer, Michael J.
    Berkowitz, Ross S.
    Wong, Kwong-Kwok
    [J]. DISEASE MARKERS, 2007, 23 (5-6) : 367 - 376
  • [33] The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers
    Hu, Zhiyuan
    Cunnea, Paula
    Zhong, Zhe
    Lu, Haonan
    Osagie, Oloruntoba I.
    Campo, Leticia
    Artibani, Mara
    Nixon, Katherine
    Ploski, Jennifer
    Gonzalez, Laura Santana
    Alsaadi, Abdulkhaliq
    Wietek, Nina
    Damato, Stephen
    Dhar, Sunanda
    Blagden, Sarah P.
    Yau, Christopher
    Hester, Joanna
    Albukhari, Ashwag
    Aboagye, Eric O.
    Fotopoulou, Christina
    Ahmed, Ahmed
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1570 - 1579
  • [34] miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
    Givel, Anne-Marie
    Kieffer, Yann
    Scholer-Dahirel, Alix
    Sirven, Philemon
    Cardon, Melissa
    Pelon, Floriane
    Magagna, Ilaria
    Gentric, Geraldine
    Costa, Ana
    Bonneau, Claire
    Mieulet, Virginie
    Vincent-Salomon, Anne
    Mechta-Grigoriou, Fatima
    [J]. NATURE COMMUNICATIONS, 2018, 9
  • [35] Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
    Jang, Ji Yon Agnes
    Yanaihara, Nozomu
    Pujade-Lauraine, Eric
    Mikami, Yoshiki
    Oda, Katsutoshi
    Bookman, Michael
    Ledermann, Jonathan
    Shimada, Muneaki
    Kiyokawa, Takako
    Kim, Byoung-Gie
    Matsumura, Noriomi
    Kaku, Tsunehisa
    Kuroda, Takafumi
    Nagayoshi, Yoko
    Kawabata, Ayako
    Iida, Yasushi
    Kim, Jae-Weon
    Quinn, Michael
    Okamoto, Aikou
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (04)
  • [36] Clinicopathologic and survival analyses of synchronous primary endometrial and epithelial ovarian cancers
    Sozen, Hamdullah
    Vatansever, Dogan
    Iyibozkurt, Ahmet Cem
    Topuz, Samet
    Ozsurmeli, Mehmet
    Salihoglu, Yavuz
    Guzelbey, Burcu
    Berkman, Sinan
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2015, 41 (11) : 1813 - 1819
  • [37] Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease
    Jazaeri, Amir A.
    [J]. MOLECULAR ONCOLOGY, 2009, 3 (02) : 151 - 156
  • [38] Early stage epithelial ovarian cancers: A study of morphologic prognostic factors
    Terzi, Aysen
    Aktas, Isil Yildiz
    Dolgun, Anil
    Ayhan, Ali
    Kucukali, Turkan
    Usubutun, Alp
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2013, 209 (06) : 359 - 364
  • [39] Evolving population-based statistics for rare epithelial ovarian cancers
    Matsuo, Koji
    Machida, Hiroko
    Matsuzaki, Shinya
    Grubbs, Brendan H.
    Klar, Maximilian
    Roman, Lynda D.
    Sood, Anil K.
    Gershenson, David M.
    Wright, Jason D.
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 157 (01) : 3 - 11
  • [40] A new paradigm of genetic testing for hereditary breast/ovarian cancers
    Kwong, Ave
    Chen, J. W.
    Shin, Vivian Y.
    [J]. HONG KONG MEDICAL JOURNAL, 2016, 22 (02) : 171 - 177